Financing Quarterly Statistics, Q2 2020

A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2020

During Q2 biopharmas brought in an aggregate $32.3bn in financings and device company fundraising totaled $9.5bn; while in vitro diagnostic firms and research tools players brought in $2bn across the period.

Quarterly Stats_1200x675

During the second quarter, biopharma financing reached $32.3bn, more than doubling Q1’s $13.8bn. The bulk of the fundraising was, like last quarter, from follow-on public offerings, which brought in $13.6bn or 42% of the Q2 total (see Exhibit 1). The stand-out of this group, and also the largest financing of the quarter was messenger RNA (mRNA) therapeutics and vaccines firm Moderna Inc.’s $1.3bn public offering [See Deal]. The company will use the proceeds to begin manufacturing its mRNA-1273 vaccine against SARS-CoV-2, the strain of coronavirus that causes COVID-19, ahead of a potential approval and launch.

Moderna is pursuing the rapid development and manufacture of mRNA-1273 in collaboration with the National Institutes of Health’s National Institute...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.